Physician Sentiment on IBRANCE®

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated 2026-07-08. KOL Pulse reports the physician conversation and does not endorse any product.

Trial 1 · NCT02947685

What do oncologists think of the PATINA trial (IBRANCE®)?

PATINA — 1L HR+/HER2+ MBC maintenance

Physicians are broadly favorable, with real nuance on PATINA: 33% of 27 verified physician voices positive, 22% nuanced (praising the result while flagging a caveat), 37% neutral, 8% critical.

33%

22%

37%

Positive 33% Nuanced 22% Neutral 37% Critical 8%

Denominator: 27 distinct verified physician voices across 60 oncologist posts, 2024-12-12 to 2026-02-08. Sponsor: Alliance Foundation Trials (funded by Pfizer)

See full PATINA conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT02947685 · NEJM 2026 — PATINA primary publication

Metzger O, Mandrekar S, DeMichele A, et al. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer. N Engl J Med. 2026;394(5):451-462.

Physician voices — verbatim

Representative positive voice

Long awaited results and very exciting advance for our patients!! Almost all of my patients still on this well tolerated quadruplet Rx. Stay tuned later this morning. @OncoAlert #SABC24

Hope Rugo

@hoperugo

Representative nuanced voice

PATINA trial: maintenance palbociclib after first line anti-HER2+chemo in HER2/HR+ metastatic BC: - PFS benefit, no OS (not mature) - significantly more toxic (including financial) - significant early censoring imbalance (estimated 6% versus 12% over first 6 months in both arms,

Timothée Olivier, MD

@Timothee_MD

Representative critical voice

PATINA #SABCS2024 ▶️ Pts have gotten through a tough chemo, if you add something toxic to their subsequent therapy, it should increase OS! ▶️ We NEED to stop saying toxicities are "manageable", the palbo group had much more toxicities, it should be said like that, without spin

Enrique Soto

@EnriqueSoto8

Full physician voice list (27)

Physician	Comment (verbatim)	Sentiment	Impressions
Timothée Olivier, MD @Timothee_MD	PATINA trial: maintenance palbociclib after first line anti-HER2+chemo in HER2/HR+ metastatic BC: - PFS benefit, no OS (not mature) - significantly more toxic (including financial) - significant early censoring imbalance (estimated 6% versu…	Nuanced	24,495
Paolo Tarantino @PTarantinoMD	Among pts with ER+/HER2+ MBC, maintenance HP (control arm) had a PFS of: -29.1 mo in PATINA -16.3 mo in HER2CLIMB-05 The difference? In PATINA all pts also received ET (only 45% in H2C-05). Reminder that, besides fancy new drugs, ET can R…	Nuanced	18,220
Erika Hamilton, MD, FASCO @ErikaHamilton9	T-DXd + pertuzumab approved for 1st L HER-2+ #bcsm! Now for the debates around induction length, maintenance, re-induction etc. My opinion: I'll induce to maximal patient response (this will likely be longer than 6 cycles), then move to m…	Neutral	15,114
Ilana Schlam @IlanaSchlam	Nice table to put this rapidly evolving field in perspective #SABCS25	Neutral	14,874
Oncology Brothers @OncBrothers	PATINA was first presented at #SABCS24 @SABCSSanAntonio and now in @NEJM! This is the SoC for 1L HR+ HER2+ mBC: Anti-HER2 + ET + Palbo after induction chemo. - mPFS 44.3mos vs 29.1mos (HR: 0.74) - #SABC25 Update: At 3yrs, improved CNS pr…	Positive	12,106
Yakup Ergün @dr_yakupergun	On DESTINIY-Breast09 before #ASCO25 The announcement of DB-09 in April 2025, showing a significant PFS advantage of T-DXd + pertuzumab over THP in HER2+ metastatic breast cancer, has generated great excitement. However, ahead of the full d…	Nuanced	11,790
Abi Siva MD @AbiSivaMD	Latest @NCCN update now supports palbociclib maintenance per PATINA. Many of us have already been doing this in practice, and this should help with insurance approvals. @ASCO @SABCSSanAntonio @OncBrothers @PTarantinoMD	Neutral	8,393
Sara Tolaney @stolaney1	PATINA CNS Progression by Otto Metzger Among pts w/no CNS mets at baseline, cumulative risk of CNS progression or death: 12.8% (palbo) vs 19.0% (control), p=0.0378 Could palbo be preventing CNS mets? caveat: no mandatory CNS imaging at ba…	Nuanced	5,830
Stephanie Graff, MD, FACP, FASCO @DrSGraff	PATINA demonstrates lower rates of CNS progression in both all pts and those with brain meta at baseline with the addition of palbociclib. @Otto_DFCI @OncoAlert #SABCS25	Positive	5,121
Gaia Griguolo @GaiaGriguolo	Maintenance palbociclib (+Pertu-Trastu in PATINA trial) can delay CNS metastases as first site of progression in HR+HER2+ metastatic breast cancer! This is such a clinically relevant result! #SABCS25 @OncoAlert	Positive	4,657
Matteo Lambertini, MD PhD @matteolambe	Other very important data from the #PATINA trial presented at #SABCS25 by the great @Otto_DFCI from @DFCI_BreastOnc showing the potential value of #palbociclib in delaying or preventing CNS involvement in HER2+/HR+ advanced #BreastCancer …	Positive	4,237
Dr Sarah Sammons @drsarahsam	While this is likely great progress for our pts, a critical eye is warranted due to impact of continuous ADC obviating maintenance which has excellent QOL. 1) Are we curing more pts? 2) Is OS improved? 3) How are pts feeling? 4) What abou…	Nuanced	3,454
Enrique Soto @EnriqueSoto8	PATINA #SABCS2024 ▶️ Pts have gotten through a tough chemo, if you add something toxic to their subsequent therapy, it should increase OS! ▶️ We NEED to stop saying toxicities are "manageable", the palbo group had much more toxicities, it …	Negative	2,174
Dr Amol Akhade @SuyogCancer	So that is how smart trial design help you to get impressive PFS results . You select pts with good biology at the end of induction chemo and then give them additional treatment that control arm good biology pts dont get and show that PFS …	Nuanced	2,044
Naoto T Ueno, MD, PhD @teamoncology	Major practice change data out now. Combination of palbociclib, anti-HER2 therapy, and endocrine therapy. For HR* HER2+ MBC. https://t.co/l9nXtBsMOd #SABCS24	Positive	1,763
Kristina Jankovic, MD @JankovicK	✨✨✨✨✨✨✨✨✨✨✨✨✨ Promising findings from #PATINA presented at #SABCS24 demonstrate a 15-month improvement in PFS with the addition of palbociclib to HER2-targeted therapy and ET as maintenance treatment in the first-line setting, compared to s…	Neutral	1,302
Hope Rugo @hoperugo	Long awaited results and very exciting advance for our patients!! Almost all of my patients still on this well tolerated quadruplet Rx. Stay tuned later this morning. @OncoAlert #SABC24	Positive	1,198
Guilherme Nader Marta @GuiNaderMarta	PROs from PATINA trial by @inesvazluis At #ESMO25 Adding palbociclib to HER2 therapy + ET in HR+/HER2+ MBC maintained HRQoL, with similar time to symptom progression (HR 0.89) & stable FACT-B TOI (66 vs 67 at 1 yr; 64 vs 67 at 3 yr) and …	Neutral	1,071
Anis Toumeh, MD @AnisToumeh	Initial thoughts: what about only 10% of patients receiving Tdxd on progression? AEs are tough too (G5 ILD). With PATINA mPFS of 44m, I am not sure this is straightforward from a change of practice standpoint.	Neutral	776
Santhosh Ambika @RenoHemonc	DB-09 -> good responders with HR+ should be deescalated to PATINA regimen..	Neutral	574
Stephanie A. Haddad, DO @DrSAHaddad	Some more highlights from Day #3 @SABCSSanAntonio #SABCS25 ✅ VIKTORIA1- 2L after ET + CDK4/6i in HR+ mBC ✅ PATINA - 1L for HR+/HER2+ mBC ✅AMBRE - 1L in HR+ mBC w. high tumor burden @drteplinsky @DanielaUruetamd @mayscancer @LSOM_…	Positive	546
Nicole Casasanta, MD @ncasasanta	10/21 #TumorBoardTuesday 🧑‍🏫Mini Tweetorial 6🧑‍🏫 🧠PATINA CNS🧠 🔹CNS mets at BL: Palbo (n=11), Control (n=9) 🔹At 36 mo, cum. incidence CNS progression/death 13.4% vs 19.9% for palbo vs control P =0.04 🔹Pts w/o CNS mets @ BL, progression 13% v…	Neutral	515
Ash Paul @pash22	The PATINA trial – palbociclib maintenance in metastatic breast cancer. What is the best 1st-line strategy in patients with HR+/HER2+ advanced/metastatic breast cancer? https://t.co/mc7IhwK2nE via @Timothee_MD @Maherjane @DrMarkLythgoe	Negative	354
Daniel A. González-Padilla @Daniel_Urologia	Long time ago I asked our Med onc colleagues if there was ever a phase 3 paper saying that AE were not manageable, apparently no one could remember one example. mortality is reported separately so you either die from the adverse events or…	Neutral	309
Eleonora Teplinsky, MD, FASCO @drteplinsky	Agree completely. Not everyone needs upfront T-DXd and the side effects of prolonged T-DXd are significant. A maintenance approach is critical. THP with maintenance tucatinib or palbociclib is an excellent option. #SABCS25	Positive	202
Adriana Kahn, MD @AdrianaKahnMD	This is amazing! It is a big step up on the ladder towards 100% but hopefully one day soon enough we will reach the top; our patients need so much better than all of that..!	Positive	139
Dr Liz O'Riordan @Liz_ORiordan	Wow!!!!!	Neutral	107

See full PATINA conference coverage & trial data →

Trial 2 · NCT03355157

What do oncologists think of the PADMA trial (IBRANCE®)?

PADMA — HR+/HER2- MBC (CDK4/6i + ET)

Physicians are broadly favorable, with real nuance on PADMA: 59% of 12 verified physician voices positive, 8% nuanced (praising the result while flagging a caveat), 33% neutral, 0% critical.

59%

33%

Positive 59% Nuanced 8% Neutral 33% Critical 0%

Denominator: 12 distinct verified physician voices across 17 oncologist posts, 2024-11-26 to 2025-01-16. Sponsor: German Breast Group / investigator-initiated

See full PADMA conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT03355157

Physician voices — verbatim

Representative positive voice

Sibylle Loibl presents Padma. Palbo plus ET improved TTF and PFS with OS trend compared to chemo. Patients should not get chemo first except in extraordinary situations. @OncoAlert #SABCS24

Hope Rugo

@hoperugo

Representative nuanced voice

PADMA trial . Results similar to right choice trial . Not many pts with viceral crisis though. @Larvol @5_utr @OncoAlert @SABCSSanAntonio #SABCS24

Dr Amol Akhade

@SuyogCancer

Full physician voice list (12)

Physician	Comment (verbatim)	Sentiment	Impressions
Sara Tolaney @stolaney1	PADMA study: ET + palbo vs chemo (cape/taxane/navelbine) in high risk HR+ MBC--> confirms ET+ cdk4/6i is 1L SOC n=150 42% w/liver mets 6% BRCAm TTF: 17.2 vs 6.1mo HR 0.46 PFS: 18.7 vs 7.8 mo, HR 0.45 OS trend: 46.1 vs 36.8 mo #SABCS24 @O…	Neutral	11,876
Oncology Brothers @OncBrothers	#SABCS24 Part 2: Highlights w/ @jamecancerdoc ✅ #EUROPA ✅ #TAILORx ✅ #PADMA ✅ #EMBER3 Full 📢: ⭐️ https://t.co/26pwXj5j8g ⭐️ https://t.co/jc9mu7uaBn ⭐️Also on “Oncology Brothers” podcast #OncTwitter #bcsm @TargetedOnc #BreastCanc…	Neutral	5,354
Hope Rugo @hoperugo	Sibylle Loibl presents Padma. Palbo plus ET improved TTF and PFS with OS trend compared to chemo. Patients should not get chemo first except in extraordinary situations. @OncoAlert #SABCS24	Positive	4,134
Erika Hamilton, MD @ErikaHamilton9	#PADMA study presented by Dr. Loibl - looking at induction chemo followed by ET maint vs. upfront ET + CDk4/6 Another study- chemo inferior to ET + CDK4/6. 🆘 No need to do this folks. Chemo 🚫doesn't help us here. #SABCS24 @SABCSSanAnton…	Positive	2,603
Elisa Agostinetto @ElisaAgostinett	At #SABCS24 LBA session - @LoiblSibylle on the PADMA trial comparing 1st line ET + Palbo vs Standard Mono-CT in High Risk HER2-/HR+ metastatic BC and indication for CT ⬆️TTF and PFS w/palbo+ET Reassuring data supporting 1st line CDK4/6i+…	Positive	2,449
Harold J. Burstein, MD, PhD, FASCO @DrHBurstein	Padma study shows that first line treatment of ER+ MBC is >> better than first line single agent chemo. ⁦@SABCSSanAntonio⁩ #sabcs24	Positive	1,954
Dr Amol Akhade @SuyogCancer	PADMA trial . Results similar to right choice trial . Not many pts with viceral crisis though. @Larvol @5_utr @OncoAlert @SABCSSanAntonio #SABCS24	Nuanced	1,722
M. Bolton @5_utr	PADMA: High risk HR+/Her2- metastatic breast cancer -> physicians choice chemo + endocrine vs endocrine + palbociclib mOS was “numerically prolonged” p=0.46 Much higher high grade heme toxicity 56.5% vs 10.3%, worse with palbociclib/end…	Neutral	1,102
Gaia Griguolo @GaiaGriguolo	PADMA trial presented at #SABCS24 today Results supporting international guidelines advocating use of ET+CdK4/6i as standard first-line treatment for HR+mBC #bcsm @OncoAlert	Positive	1,074
Armando Orlandi @ArmandOrlandi	Cowabunga! Riding Breast Cancer's Biggest Data’s Wave 🏄🏻‍♂️🌊🤙🏻from #SABCS24 🎯 PADMA Phase III confirms what we already knew: CDK4/6i+ET is the way! Even in high-risk HR+/HER2- mBC with 'chemo indication' • TTF: 17.2 vs 6.1 mo • PFS: 18.7 …	Positive	954
José Sandoval @JLSandoval	PADMA study (ET+Palbo vs Chemo as 1L in MBC w/ indication for 1L chemo). Increased TTF & PFS w/ 1L ET+Palbo. Similar OS. Similar results to Right Choice w/ Ribo. Soon results from AMBER w/ Abema. Yet, evidence seems to support ET+CDK4/6i as…	Positive	176
Dr Michael Copeman @drmcopeman	Outside clinical trials (with highly treatment-adherent patients, closely monitored), we need to find ways to improve compliance with CDK4/6 inhibitors plus endocrine therapies. Patients need interim goals (tumour marker changes) and proac…	Neutral	19

See full PADMA conference coverage & trial data →

Regulatory

IBRANCE® — FDA status

FDA APPROVEDIBRANCE® (palbociclib) is FDA-approved for multiple breast-cancer settings. For the full, current list of FDA indications and prescribing information, see ibrance.com or FDA label (DailyMed). KOL Pulse indexes the physician conversation; the label is owned and maintained by the manufacturer.

Frequently Asked

IBRANCE® sentiment — FAQ

PATINA

What do oncologists think of the PATINA trial (IBRANCE®)?

Across 27 verified physician voices in KOL Pulse's index for PATINA, 33% expressed positive sentiment, 22% were nuanced (praising the result while flagging a caveat), 37% were neutral, and 8% were critical. Positive voices highlight the progression-free-survival benefit and a lower rate of CNS progression when palbociclib is added to anti-HER2 maintenance; nuanced and critical voices flag immature overall survival and added toxicity, including financial toxicity.

Where can I find the PATINA trial data for IBRANCE® (palbociclib)?

PATINA is registered as NCT02947685 and studied IBRANCE® (palbociclib) in 1L HR+/HER2+ MBC maintenance. For the full PATINA trial data and conference coverage, see the KOL Pulse PATINA trial profile at kolpulse.com/kol-pulse-trial-profile-patina.

PADMA

What do oncologists think of the PADMA trial (IBRANCE®)?

Across 12 verified physician voices in KOL Pulse's index for PADMA, 59% expressed positive sentiment, 8% were nuanced (praising the result while flagging a caveat), 33% were neutral, and 0% were critical. Positive voices highlight the CDK4/6-inhibitor-plus-endocrine-therapy backbone as a chemo-sparing option in high-risk HR+/HER2- disease; nuanced and critical voices flag overall-survival maturity and patient-selection questions.

Where can I find the PADMA trial data for IBRANCE® (palbociclib)?

PADMA is registered as NCT03355157 and studied IBRANCE® (palbociclib) in HR+/HER2- MBC (CDK4/6i + ET). For the full PADMA trial data and conference coverage, see the KOL Pulse PADMA trial profile at kolpulse.com/kol-pulse-trial-profile-padma.

Regulatory

Is IBRANCE® (palbociclib) FDA approved?

IBRANCE® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.

Methodology

How this index is built

KOL Pulse indexes verbatim posts from verified oncology physicians and rolls sentiment up per clinical trial. Each physician is counted once per trial, at their highest-reach post. Sentiment is classified from the verbatim text (positive / nuanced / neutral / critical), where "nuanced" marks a voice that praises the result while flagging a substantive caveat (immature overall survival, toxicity, or trial-design/selection concerns). Institutional, media, finance, and non-physician accounts are excluded from the denominator. Quotes are reproduced verbatim and attributed to the physician's public post. KOL Pulse organizes this page by clinical trial — the maintainable unit — and links out to the manufacturer's brand site and the FDA label for the full indication list, which the manufacturer owns and updates. Trial efficacy figures are held for medical-expert verification before publication. This page reports the physician conversation; it is not medical advice and does not endorse any product.